市場調查報告書

全球血友病病治療市場:成長,趨勢,及預測(2020年∼2025年)

Von Willebrand Disease Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921911
出版日期 內容資訊 英文 111 Pages
商品交期: 2-3個工作天內
價格
全球血友病病治療市場:成長,趨勢,及預測(2020年∼2025年) Von Willebrand Disease Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 111 Pages
簡介

全球血友病病治療市場,由於必要治療的患者的醫療費的增加和支援計劃的增加,預計帶動成長。尤其是北美,進步的治療選擇的需求劇增,新技術的早期採用,患者支援計劃的增加而領導市場。但,疾病相關的認識缺乏和治療的高成本,可能成為在預測期間內的市場成長的主要障礙之一。

本報告提供全球血友病病治療市場的相關調查,市場機會和趨勢,成長及阻礙因素,各疾病類型、治療類型、給藥途徑、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 患者支援計劃的增加
    • 醫療保健支出的增加
  • 市場阻礙因素
    • 認識不足
    • 治療費用高
  • 波特的五力分析

第5章 市場區隔

  • 各疾病類型
    • 類型1
    • 類型2
    • 類型3
    • 後天性血友病病
  • 治療類型
    • 去氨加壓素
    • 替代療法
    • 凝固穩定劑
    • 其他
  • 各給藥途徑
    • 口服
    • 注射
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • CSL Behring
    • Ferring Pharmaceuticals
    • Grifols, SA
    • Octapharma AG
    • Pfizer, Inc.
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
    • 武田藥品工業株式會社

第7章 市場機會及今後趨勢

目錄
Product Code: 67087

Market Overview

According to the World Federation of Hemophilia, Von Willebrand disease is a very common bleeding defect. People suffering from the Von Willebrand disease have a defect in the protein present in their blood, known as the Von Willebrand factor. The Von Willebrand factor helps the cells present in the blood vessel called platelets, to form a clot to control and stop bleeding.

Von Willebrand disease is a frequent inherited disorder that affects both sexes. The growing healthcare expenditure and rising number of assistance programs for patients who need treatment of von Willebrand disease are expected to drive the von Willebrand disease treatment market. However, the lack of awareness about the disease and the high cost of the treatment is among the major barrier to the growth of this market over the forecast period.

Scope of the Report

As per the scope of the report, Von Willebrand disease (VWD) is a genetic disorder that delays the process of blood clotting. It is generally caused by missing or defective von Willebrand factor (VWF), a clotting protein. VWF binds factor VIII, a key clotting protein, and platelets in blood vessel walls. Desmopressin is a common drug used for the treatment of Von Willebrand disease, which is an antidiuretic hormone that triggers the release of VWF into the plasma and may increase levels of factor VIII.

Key Market Trends

Desmopressin Segment is Expected to Register a Significant Growth in the Forecast Years

By treatment type, the market has been segmented into Desmopressin, Replacement Therapies, Clot-stabilizing Medications, and others. Desmopressin stimulates the release of VWF from cells, which also increases FVIII. This is considered to be the most preferred treatment option for patients with type 1, who account for approximately 70% to 80% of cases.

Type 1 and some subtypes of type 2 von Willebrand disease have more effective results with desmopressin as compared to the other types and thus it is expected to grow during the forecast period. In addition, growing healthcare expenditure and a large patient pool also contribute to the growth of the von Willebrand disease treatment market.

North America Leads the Von Willebrand Disease Treatment Market

North America is found leading the market owing to the upsurge in the demand for progressive treatment options, early adoption of new technologies and an increase in patient assistance programs. According to the National Hemophilia Foundation, VWD is the most common bleeding disorder, affecting up to 1% of the US population.

Europe and the Asia Pacific are followed next after North America owing to the presence of a diversified patient pool, emerging economies, and a rise in the collaboration of domestic and international companies in these regions, thus driving this market.

Competitive Landscape

The von willebrand disease treatment market is competitive and many of the global players are into the market. For instance - Bayer AG, CSL Behring, Ferring Pharmaceuticals, Grifols, Octapharma AG, Pfizer, Sanofi, Sun Pharmaceutical and Takeda are providing these products across the globe.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Patient Assistance Programs
    • 4.2.2 Growing Healthcare Expenditure
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness
    • 4.3.2 High Cost of Treatment
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Disease Type
    • 5.1.1 Type 1
    • 5.1.2 Type 2
    • 5.1.3 Type 3
    • 5.1.4 Acquired VWD
  • 5.2 Treatment Type
    • 5.2.1 Desmopressin
    • 5.2.2 Replacement Therapies
    • 5.2.3 Clot-stabilizing Medications
    • 5.2.4 Others
  • 5.3 Route of Administration
    • 5.3.1 Oral
    • 5.3.2 Injection
    • 5.3.3 Other
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 CSL Behring
    • 6.1.2 Ferring Pharmaceuticals
    • 6.1.3 Grifols, S.A.
    • 6.1.4 Octapharma AG
    • 6.1.5 Pfizer, Inc.
    • 6.1.6 Sanofi S.A.
    • 6.1.7 Sun Pharmaceutical Industries Ltd.
    • 6.1.8 Takeda Pharmaceutical Company Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS